AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $42.38.

Several equities analysts have weighed in on ANAB shares. HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and raised their price target for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. Wedbush restated an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a report on Thursday, May 29th. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Guggenheim restated a "buy" rating and set a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. Finally, JPMorgan Chase & Co. raised their price target on AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. First Light Asset Management LLC lifted its stake in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company's stock worth $86,139,000 after acquiring an additional 3,764,720 shares during the last quarter. Fairmount Funds Management LLC bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $24,050,000. Boxer Capital Management LLC bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $17,212,000. Sanofi bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $10,882,000. Finally, Soleus Capital Management L.P. bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $5,481,000.

AnaptysBio Stock Down 3.9%

NASDAQ ANAB opened at $22.47 on Monday. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $41.31. The stock's 50-day moving average price is $21.67 and its 200-day moving average price is $18.38. The company has a market capitalization of $660.17 million, a P/E ratio of -4.63 and a beta of -0.26.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 282.47% and a negative net margin of 125.70%. The firm had revenue of $27.77 million during the quarter, compared to analysts' expectations of $15.27 million. Research analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio announced that its board has initiated a stock repurchase plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.